SCHEDULE 13G/A: Frazier Life Sciences Funds Update Passive Stake in Eledon Pharmaceuticals
Beneficial Ownership Amendment
Frazier Life Sciences and affiliated entities have filed an amended Schedule 13G/A, disclosing their updated passive beneficial ownership in Eledon Pharmaceuticals, Inc. as of December 31, 2024.
Summary
- Frazier Life Sciences Public Fund, L.P. and its general partners (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 878,080 shares of Eledon Pharmaceuticals Common Stock, representing 1.5% of the class.
- Frazier Life Sciences Public Overage Fund, L.P. and its general partners (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 258,998 shares, representing 0.4% of the class.
- Frazier Life Sciences X, L.P. and its general partners (FHMLS X, L.P. and FHMLS X, L.L.C.) collectively beneficially own 13,062 shares, representing 0.0% of the class.
- Frazier Life Sciences XI, L.P. and its general partners (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 26,595 shares, representing 0.0% of the class.
- Individual members James N. Topper and Patrick J. Heron each beneficially own 1,176,735 shares, representing 2.0% of the class, through their shared voting and dispositive power over shares held by multiple Frazier Life Sciences funds.
- Individual members Albert Cha and James Brush each beneficially own 1,137,078 shares, representing 1.9% of the class, through their shared voting and dispositive power over shares held by Frazier Life Sciences Public Fund, L.P. and Frazier Life Sciences Public Overage Fund, L.P.
- Individual member Daniel Estes beneficially owns 26,595 shares, representing 0.0% of the class, through shared voting and dispositive power over shares held by Frazier Life Sciences XI, L.P.
- The percentages are calculated based on 59,739,275 shares of Common Stock outstanding as of November 8, 2024, as reported in Eledon Pharmaceuticals' Form 10-Q filed on November 12, 2024.
Sentiment
Score: 5
Explanation: The document is a factual, regulatory filing disclosing beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by institutional investors, common in the biotechnology and pharmaceutical sectors where specialized funds often take positions in emerging companies like Eledon Pharmaceuticals. It reflects a passive investment stance by Frazier Life Sciences, a prominent life sciences investment firm.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, confirming a passive investment approach by Frazier Life Sciences funds. This typically indicates a long-term, non-activist stance.
Key Dates
| Date | Description |
|---|---|
| 2016-03-29 | Date Power of Attorney for James N. Topper and Patrick J. Heron was filed with the SEC (original filing). |
| 2017-07-31 | Date Power of Attorney for James N. Topper and Patrick J. Heron was filed with the SEC (updated filing). |
| 2021-08-16 | Date Power of Attorney for Albert Cha and James Brush was filed with the SEC. |
| 2022-04-18 | Date Power of Attorney for Daniel Estes was filed with the SEC. |
| 2024-11-08 | Date 59,739,275 shares of Common Stock of Eledon Pharmaceuticals, Inc. were outstanding. |
| 2024-11-12 | Date Eledon Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q was filed with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G/A statement. |
| 2025-02-14 | Date of the Joint Filing Agreement and the filing date of this Schedule 13G/A. |
Keywords
Eledon Pharmaceuticals, Frazier Life Sciences, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.